PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

The role of topical glucocorticoids in the treatment of rhinosinusitis.

Abstract The guidelines of the European position paper on rhinosinusitis and nasal polyps (EPOS, 2012) ascribe the highest strength and the most comprehensive evidence-based significance to the application of intranasal glucocorticosteroids (inGCS) as the first-line therapy for the patients presenting with acute and polypous rhinosinusitis; moreover they are recommended as the medications of choice for the treatment of chronic rhinosinusitis in the absence of polyps. The author presents the data concerning the mechanism of action, clinical effectiveness, and safety of inGCS used for the treatment of acute, recurrent, and chronic rhinosinusitis. It is shown that mometason furoate produces the favourable therapeutic effect and is possessed of beneficial pharmacodynamic and pharmacokinetic properties in the cases of its topical application. The comparative randomized clinical study (RCS) of the new preparation of mometason furoate in the form of the intranasal spray (manufactured by 'Teva' Ltd.) registered in the Russian Federation in 2015 has demonstrated that it can be considered as a therapeutic equivalent to nasonex.
PMID
Related Publications
Authors

Mayor MeshTerms
Keywords
Journal Title vestnik otorinolaringologii
Publication Year Start




PMID- 28514369
OWN - NLM
STAT- In-Data-Review
DA  - 20170517
LR  - 20170517
IS  - 0042-4668 (Print)
IS  - 0042-4668 (Linking)
VI  - 82
IP  - 2
DP  - 2017
TI  - [The role of topical glucocorticoids in the treatment of rhinosinusitis].
PG  - 70-73
LID - 10.17116/otorino201782270-73 [doi]
AB  - The guidelines of the European position paper on rhinosinusitis and nasal polyps 
      (EPOS, 2012) ascribe the highest strength and the most comprehensive
      evidence-based significance to the application of intranasal glucocorticosteroids
      (inGCS) as the first-line therapy for the patients presenting with acute and
      polypous rhinosinusitis; moreover they are recommended as the medications of
      choice for the treatment of chronic rhinosinusitis in the absence of polyps. The 
      author presents the data concerning the mechanism of action, clinical
      effectiveness, and safety of inGCS used for the treatment of acute, recurrent,
      and chronic rhinosinusitis. It is shown that mometason furoate produces the
      favourable therapeutic effect and is possessed of beneficial pharmacodynamic and 
      pharmacokinetic properties in the cases of its topical application. The
      comparative randomized clinical study (RCS) of the new preparation of mometason
      furoate in the form of the intranasal spray (manufactured by 'Teva' Ltd.)
      registered in the Russian Federation in 2015 has demonstrated that it can be
      considered as a therapeutic equivalent to nasonex.
FAU - Shakhova, E G
AU  - Shakhova EG
AD  - Volgograd State Medical University, Ministry of Health of the Russian Federation,
      Volgograd, Russian Federation.
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Mesto topicheskikh gliukokortikosteroidov v lechenii rinosinusita.
PL  - Russia (Federation)
TA  - Vestn Otorinolaringol
JT  - Vestnik otorinolaringologii
JID - 0416577
CRDT- 2017/05/18 06:00
PST - ppublish
SO  - Vestn Otorinolaringol. 2017;82(2):70-73. doi: 10.17116/otorino201782270-73.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>